Nature of Business (Details)				3 Months Ended		6 Months Ended
	Jul. 09, 2024 USD ($) $ / shares shares	Jun. 05, 2024 shares	Apr. 22, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2024 USD ($) segment shares	Jun. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Nature of business:
Number of operating segments | segment						2
Accumulated deficit				$ 229,264,005		$ 229,264,005		$ 225,704,176
Net Income (Loss)				(1,644,502)	$ (1,612,024)	(3,559,829)	$ (2,658,133)
Net cash used in operating activities						(3,260,309)	(4,089,580)
Cash and cash equivalents				9,412,539	13,160,939	9,412,539	13,160,939	8,446,158	$ 13,359,615
Net increase in cash and cash equivalents						$ 966,381	(198,676)
Percentage change in cash and cash equivalent						11.00%
Working capital				3,308,260		$ 3,308,260		$ 3,355,212
Increase (decrease) in working capital						$ (46,952)
Working capital increase (decrease) as a percent						1.00%
Reclassification of convertible debt from non-current to current Liability				1,000,000		$ 1,000,000
Shares issued price per share | $ / shares			$ 6.40
Issuance costs				$ 625,065	$ 834,061	$ 625,065	$ 834,061
Fractional shares issued in reverse stock split (Shares) | shares		0
Reverse stock spilt effective from June 5, 2024		0.0625
Public Offering
Nature of business:
Exercise price of warrants | $ / shares			$ 0.02
Total gross proceeds			$ 4,750,000
Issuance costs			$ 450,000
Expiration term of warrants			5 years
Common Stock
Nature of business:
Fractional shares issued in reverse stock split (Shares) | shares				114,735		114,735
Issuance of common stock for purchase option (in shares) | shares					1,978		1,978
Common Stock | Public Offering
Nature of business:
Number of shares issued | shares			204,694
Exercise price of warrants | $ / shares			$ 6.40
Subsequent Event
Nature of business:
Number of common warrants to purchase shares issued | shares	703,125
Exercise price of warrants | $ / shares	$ 6.00
Proceeds from the exercise of pre-funded warrants	$ 4,218,750
Pre-funded warrants | Public Offering
Nature of business:
Number of common warrants to purchase shares issued | shares			537,500
Common warrants | Public Offering
Nature of business:
Number of common warrants to purchase shares issued | shares			742,194
HyBryte
Nature of business:
Revenue from collaborative arrangement						$ 1,100,000
Term (in years)						4 years
NIH
Nature of business:
Government grant funding				$ 554,000		$ 554,000